Antonio Culebras, MD
Neurology · Syracuse, NYNPI 1295793990
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $32,660 of the $45,457 with a category attached, or 71.8%. Jazz Pharmaceuticals Inc. accounts for 99.1% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $30,586 and has fallen 99.2% since, to $250 in 2025. Among neurology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 56 payments — averaging $811.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$45K
- Resmed Corp$300
- Harmony Biosciences LLC$91
- Axsome Therapeutics, Inc.$17
What the payments were for
- Consulting fees$4,2509%
- Speaking & faculty fees$32,66072%
- Travel & lodging$7,13416%
- Food & beverage$1,0972%
- Education$3161%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 51 | $45,049 |
| Resmed Corp | 1 | $300 |
| Harmony Biosciences LLC | 3 | $91 |
| Axsome Therapeutics, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$45,457 in reported general payments places this provider in the 90th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 22 | $407,643 |
| Modafinil | 40 | $16,632 |
| Eszopiclone | 15 | $3,444 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 23 | $1,851 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 46 | $496 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 16 | $437 |
| Clonazepam | 27 | $345 |
| Ropinirole Hcl | 33 | $339 |
| Gabapentin | 33 | $245 |
| Fluoxetine Hcl | 11 | $17 |
Paid to pharmacies, not to this prescriber.
Other neurology in Syracuse
- Idan SharonBrooklyn$2.1M
- Allan PerelStaten Island$1.7M
- Nicolas SaikaliAmherst$1.5M
- David KreitzmanCommack$1.5M
- Charles ArgoffAlbany$1.2M
- Stephen KriegerNew York$1.1M
- Robert FeketeHawthorne$1M
- Jennifer McVigeAmherst$982K
- Warren SpinnerPort Jefferson Station$791K
- Richard LiptonBronx$753K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.